Dr. James P. Maynard, M.D.
Neurology (Neurology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
KY license 40199 -
Sleep Medicine (Psychiatry & Neurology) Physician
KY license 40199 -
Specialist
KY license 40199
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 3 payments worth $1,678 in total to this clinician.
| Amgen Inc. | $1,678 |
|---|
| Travel and Lodging | $1,678 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Nov 10, 2025 | Travel and Lodging travel to Seattle, WA · in-kind | $632 |
| Amgen Inc. Nov 10, 2025 | Travel and Lodging travel to Seattle, WA · in-kind | $555 |
| Amgen Inc. Nov 10, 2025 | Travel and Lodging travel to Seattle, WA · in-kind | $491 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 29 industry-funded studies in 2025, from 8 companies. The companies reported $3,438,898 in research payments for these studies, mostly to the institutions running them.
- A phase 1 randomized and phase 2 study to evaluate the safety tolerability immunogenicity and immunopersistence of a clostridioides difficile vaccine administered in a 2DOSE regimen with novel adjuvants in healthy adults
Pfizer Inc. - A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly and Company · Completed · NCT06373146 - A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06649045 - A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929079 - A phase 3 protocol to investigate the safety tolerability and immunogenicity of BNT162B2 rnabased variantadapted vaccine candidates against SARSCOV2 in participants 12 through 64 years of age considered at higher risk…
Pfizer Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - A phase 1 randomized doubleblind sponsoropen study to describe the safety and tolerability of a multivalent pneumococcal conjugate vaccine in adults
Pfizer Inc. - A phase 1 randomized doubleblind thirdpartyunblinded study to evaluate the safety and tolerability of a vaccine against e coli in healthy adults
Pfizer Inc. - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.